David Ebsworth

Last updated
David Ebsworth
Born1954 (age 69–70)
NationalityBritish
EducationDuke of Yorks Royal Military School
Alma mater University of Surrey
OccupationNon-Executive Chairman
Years active1980-
Known forChairman, Pharmaceutical industry

David Ebsworth is non-executive chairman at Verona Pharma Plc. His career spans over 35 years in the global pharmaceutical industry, during which he was Global Head of Pharmaceuticals at Bayer AG and CEO of a number of companies, including ViforPharma and Galenica. He is also an advisor to a variety of CEOs at public and private organisations. [1]

Contents

Education

Ebsworth was educated in Germany, Singapore and England at the Duke of Yorks Royal Military School He gained his BSc in chemistry and German in 1976 and his Ph.D. in industrial relations in 1980 from the University of Surrey. [2] Ebsworth received an honorary doctorate from the University of New Haven in 2000. [3]

In 2001, he was awarded the ‘Global Citizen of the Year’ award from the Seton Hall University in New Jersey. [4]

Career

Ebsworth began his career at Pfizer in Germany. In 1983, he moved to Bayer AG, where he ultimately served as the president of North American business and the global head of pharmaceuticals. [5] He was with the company for more than 19 years before he resigned in 2002. [6]

After working at Bayer, Ebsworth was named the chief executive officer of Oxford Glycosciences, a biotech company listed on the London Stock Exchange and Nasdaq. Following the company's sale to Celltech in 2003, he became chairman of a number of organisations, such as Wilex AG and A&D Pharma Holdings NV, [7] as well as joining the board at SkyePharma PLC and other companies. [8]

Ebsworth was the CEO of Vifor Pharma for 5 years from 2009, and also the CEO of Galencia Group from 2011. [9] Notably, during his tenure as the CEO of Galenica Group, the company's value increased from CHF 2.4 billion to CHF 5.6 billion, with the company receiving two FDA approvals and one EMA approval. [10]

Ebsworth is currently an advisor to the CEO of Vifor Pharma and Galencia Santé, which now has a market cap of just under $10bn. [11]

In 2013, he set up the David Ebsworth Scholarship, which was worth £3,000 per year for four years, to help students who wanted to study German at the University of Surrey. Here, he has also founded the David Ebsworth Prize for Best Performance in the Professional Training Year and the David Ebsworth Student Opportunities Fund. [12]

Non-Executive Positions

Ebsworth is non-executive chairman of the board of directors at Verona Pharma, the drug development company focused on respiratory disease treatment. [13]

He has served on a number of boards across the pharma, biotech and healthcare sectors, in the UK, Germany, the US, Austria, Italy, Israel, Netherlands, and Japan. He has also advised venture capital and private equity companies. [14]

Related Research Articles

<span class="mw-page-title-main">Gedeon Richter (company)</span> Hungarian pharmaceutical company

Gedeon Richter Plc. is a European multinational pharmaceutical and biotechnology company headquartered in Budapest. It is the largest pharmaceutical company in Central and Eastern Europe, with an expanding direct presence in Western Europe, China, Northern America and Latin America. Richter has the largest R&D unit in Central and Eastern Europe and operations in over 100 countries.

Bausch Health Companies Inc. is an American-Canadian multinational specialty pharmaceutical company based in Laval, Quebec, Canada. It develops, manufactures and markets pharmaceutical products and branded generic drugs, primarily for skin diseases, gastrointestinal disorders, eye health and neurology. Bausch Health owns Bausch & Lomb, a supplier of eye health products. Bausch Health's business model is primarily focused on acquiring small pharmaceutical companies and then sharply increasing the prices of the drugs these companies sell.

<span class="mw-page-title-main">Daniel Vasella</span>

Daniel Lucius Vasella is a Swiss medical doctor, author, and executive who served as CEO and chairman of the Swiss pharmaceutical company Novartis AG, the world's fifth largest drug company. During his tenure Novartis shares fell 10%, compared to the industry average. In February 2013 Vasella was awarded close to $78 million in a "golden handshake"

<span class="mw-page-title-main">Actavis</span> Global pharmaceutical company

Actavis Generics is a global pharmaceutical company focused on acquiring, developing, manufacturing and marketing branded pharmaceuticals, generic and over-the-counter medicines, and biologic products. Actavis has a commercial presence across approximately 100 countries. The company has global headquarters in Dublin, Ireland and administrative headquarters in Parsippany-Troy Hills, New Jersey, United States.

<span class="mw-page-title-main">Helmut Panke</span> German manager, physicist and businessman

Helmut Gunter Wilhelm Panke is a German manager and physicist who has been holding board membership in several companies - Microsoft, Bayer AG and Singapore Airlines. During the past recent 30 years, Panke's management career spread over several companies, including e.g. serving as the chairman of the board of management at BMW AG from May 2002 through August 2006.

John Mendlein is a biotech executive who has held leadership positions in biotech companies in Boston, San Diego and Toronto.

Fred Hassan, is a Pakistan-born American business executive who works for Warburg Pincus and was CEO of three global pharmaceutical companies.

<span class="mw-page-title-main">Stada Arzneimittel</span> German pharmaceutical company

Stada Arzneimittel AG is a pharmaceutical company based in Bad Vilbel, Germany which specializes on a three-pillar strategy consisting of consumer healthcare products, generics and specialty pharma. Worldwide, STADA Arzneimittel AG sells its products in approximately 120 countries. In 2022, revenue totaled €3.79 billion.

<span class="mw-page-title-main">Joseph Jimenez</span>

Joseph Jimenez is the former CEO of the Swiss pharmaceutical company Novartis.

<span class="mw-page-title-main">Trevor M. Jones</span>

Trevor Mervyn Jones, CBE PhD DSc (Hon) FRCP FMedSci FBPhS FRSM FRSC FLSW is a visiting professor at King's College London, and a former Head of R&D, at Wellcome. He continues to have a distinguished career in the pharmaceutical and biotech industry as well as in academia.

Marijn Emmanuel Dekkers is a Dutch-American former pharmaceutical businessman. He was CEO of Bayer AG from 2010 to 2016. He served as CEO of Thermo Fisher Scientific Inc. from 2002 to 2009. He served as Chairman of Unilever from 2016 to 2019. He is also Founder and Chairman of Novalis LifeSciences LLC, an investment and advisory firm for the Life Science industry.

David Edmund Ian Pyott CBE was the CEO of Allergan, a pharmaceutical company from 1998 to 2015, when Allergan was acquired by Actavis. In 2014 he was one of the 25 highest-paid CEOs in the United States.

The Biotechnology Innovation Organization (BIO) is the largest advocacy association in the world representing the biotechnology industry. It was founded in 1993 as the Biotechnology Industry Organization from a merger of the Industrial Biotechnology Association (IBA) and the Association of Biotechnology Companies (ABC), and changed its name to the Biotechnology Innovation Organization on January 4, 2016. Biotechnology Innovation Organization serves more than 1,100 biotechnology firms, research schools, state biotechnology centers and related associations in the United States and in more than 30 other countries.

CSL Vifor is a global specialty pharmaceuticals company in the treatment areas of iron deficiency, dialysis, nephrology & rare disease. It is headquartered in Switzerland and consists of CSL Vifor, Vifor Fresenius Medical Care Renal Pharma (VFMCRP) and Sanifit Therapeutics.

Galenica AG, headquartered in Bern, is an internationally active Swiss pharmaceutical and logistics company group, named after the ancient physician Galenus. It dates back to the 1927 Collaboration Pharmaceutique SA, a purchasing center for pharmaceutical products founded by 16 pharmacists in Clarens. This was renamed to Galenica AG in 1932 and moved from Vaud's Le Châtelard to Bern. The Galenica shares are listed on the SIX Swiss Exchange and are a component of the SMI MID index.

Etienne Jean Jornod is a Swiss entrepreneur and manager. He was Chairman of the Board of Directors of the pharmaceutical and logistics group Galenica and the NZZ Mediengruppe.

<span class="mw-page-title-main">William Rastetter</span> American scientist, entrepreneur and venture capitalist

William H.Rastetter, a scientist, entrepreneur and venture capitalist, is the chair of Neurocrine Biosciences, of Fate Therapeutics, and of Daré Bioscience, Inc. in San Diego, California. He is a founding board member and investor in GRAIL, Inc. in Menlo Park, California, and served for a period as the company's interim CEO (2017) and chair (2017-2018). Rastetter is also a director of Regulus Therapeutics and Entos, Inc.. He was a partner in the venture firm Venrock (2006-2013), and a trustee at Caltech (2015-2018). He has served as a director (1998-2016) and as chair of Illumina (2005-2016). He advised SVB Leerink (2014-2019) and currently advises Illumina Ventures.

Idorsia is a Swiss pharmaceutical research company in Allschwil, near Basel, Switzerland.

<span class="mw-page-title-main">Joaquin Duato</span> American corporate executive

Joaquin Duato is a Spanish-American business executive. Duato is a dual citizen of Spain and the United States. He is the chairman and chief executive officer (CEO) of Johnson & Johnson, an American multinational conglomerate. He is the eighth person to serve as CEO of Johnson & Johnson since it became a publicly-traded company in 1944.

<span class="mw-page-title-main">Bill Anderson (businessman)</span> American business executive (born 1966)

William Anderson is an American business executive who has been the chief executive officer (CEO) of Bayer AG since June 2023.

References

  1. ↑ "Stocks". Bloomberg News .
  2. ↑ "Stocks". Bloomberg News .
  3. ↑ "Dr. David Ebsworth Assumes Worldwide Management Responsibility for The Pharmaceutical Business". Archived from the original on 2016-06-24.
  4. ↑ "Stocks". Bloomberg News .
  5. ↑ "Stocks". Bloomberg News .
  6. ↑ Kapner, Suzanne (9 January 2002). "In Upheaval within Bayer, Chief Resigns at Drug Unit". The New York Times.
  7. ↑ "A&D Pharma HLDGS N.V | Statement re A&D PHARMA TO APPOINT NEW MANA... | InvestEgate".
  8. ↑ "SkyePharma Makes Non-Executive Board Appointment; David Ebsworth to Join Board of Directors". Archived from the original on 2016-06-24.
  9. ↑ "Verona Pharma - Board". Archived from the original on 2016-11-06. Retrieved 2016-05-25.
  10. ↑ "Galenica Prepares to Split in Two as CEO Ebsworth Steps Down". Bloomberg.com. 12 August 2014.
  11. ↑ "Verona Pharma - Board". Archived from the original on 2016-11-06. Retrieved 2016-05-25.
  12. ↑ "David Ebsworth Scholarship for 2013 - University of Surrey - Guildford". www.surrey.ac.uk. Archived from the original on 2013-05-08.
  13. ↑ "Dr David Ebsworth Appointed as Non-Executive Chairman - RNS - London Stock Exchange". Archived from the original on 2016-06-24. Retrieved 2016-05-25.
  14. ↑ "Dr David Ebsworth Appointed as Non-Executive Chairman - RNS - London Stock Exchange". Archived from the original on 2016-06-24. Retrieved 2016-05-25.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.